BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET
Company Participants
John Bluth - Chief Communications Officer
Jon Stonehouse - CEO
Charlie Gayer - Chief Commercial Officer
Anthony Doyle - CFO
Helen Thackray - Chief R&D Officer
Jinky Rosselli - Chief Data and Insights Officer
Conference Call Participants
Nick Lenard - JPMorgan
Tazeen Ahmad - Bank of America
Brian Abrahams - RBC Capital Markets
Maury Raycroft - Jefferies
Stacy Ku - TD Cowen
Liisa Bayko - Evercore ISI
Gena Wang - Barclays
Serge Belanger - Needham & Company
Operator
Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to John Bluth, Chief Communications Officer. Please go ahead.
John Bluth
Thanks, Dave. Good morning and welcome to BioCryst Third Quarter 2024 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray; and Chief Data and Insights Officer, Jinky Rosselli. Following our remarks, we'll answer your questions.
Today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation.
You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with
- Read more current BCRX analysis and news
- View all earnings call transcripts